IP Library › Granted Patent US 7,943,743

Granted Patent B2

US 7,943,743 · App. 11/917,727 · Granted May 17, 2011

Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,943,743
App. No.: 11/917,727
Granted: May 17, 2011
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.

Claims (124)

1. An isolated human monoclonal antibody, or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof cross-competes for binding to PD-L1 with a reference antibody or reference antigen-binding portion thereof comprising:

(a) a human heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:1 and a human light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:11;

(b) a human heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:2 and a human light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:12;

(c) a human heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:3 and a human light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:13;

(d) a human heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:4 and a human light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:14;

(e) a human heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:5 and a human light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:15;

(f) a human heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:6 and a human light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:16;

(g) a human heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:7 and a human light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:17;

(h) a human heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:8 and a human light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:18;

(i) a human heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:9 and a human light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:19; or

(j) a human heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:10 and a human light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:20.

2. The antibody or antigen-binding portion thereof of claim 1 , wherein the human heavy chain variable region comprises amino acids having the sequence set forth in SEQ ID NO:1 and the human light chain variable region comprises amino acids having the sequence set forth in SEQ ID NO:11.

3. The antibody or antigen-binding portion thereof of claim 1 , wherein the human heavy chain variable region comprises amino acids having the sequence set forth in SEQ ID NO:2 and the human light chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 12.

4. The antibody or antigen-binding portion thereof of claim 1 , wherein the human heavy chain variable region comprises amino acids having the sequence set forth in SEQ ID NO:3 and the human light chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 13.

5. The antibody of claim 1 , wherein the antibody binds to human PD-L1 with a K D of 5×10 −9 M or less.

6. The antibody of claim 1 , wherein the antibody binds to human PD-L1 with a K D of 2×10 −9 M or less.

7. An isolated human monoclonal antibody, or an antigen-binding portion thereof, comprising:

(a) a heavy chain variable region that comprises amino acids having a sequence derived from a human V H 1-18 germline sequence; and

(b) a light chain variable region that comprises amino acids having a sequence derived from a human V K L6 germline sequence;

wherein the antibody specifically binds to PD-L1.

8. An isolated human monoclonal antibody, or an antigen-binding portion thereof, comprising:

(a) a heavy chain variable region that comprises amino acids having a sequence derived from a human V H 1-69 germline sequence; and

(b) a light chain variable region that comprises amino acids having a sequence derived from a human V K L6 germline sequence; wherein the antibody specifically binds to PD-L1.

9. An isolated human monoclonal antibody, or an antigen-binding portion thereof, comprising:

(a) a heavy chain variable region that comprises amino acids having a sequence derived from a human V H 1-3 germline sequence; and

(b) a light chain variable region that comprises amino acids having a sequence derived from a human V K L15 germline sequence; wherein the antibody specifically binds to PD-L1.

10. An isolated monoclonal antibody, or antigen binding portion thereof, comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein the heavy chain variable region and light chain variable region CDR3 domains are selected from the group consisting of:

(a) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:41; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:71 and conservative modifications thereof;

(b) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:42; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:72 and conservative modifications thereof;

(c) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:43; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:73 and conservative modifications thereof;

(d) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:44; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:74 and conservative modifications thereof;

(e) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:45; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:75 and conservative modifications thereof;

(f) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:46; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:76 and conservative modifications thereof;

(g) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:47; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:77 and conservative modifications thereof;

(h) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:48; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:78 and conservative modifications thereof;

(i) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:49; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:79 and conservative modifications thereof; and

(j) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:50; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:80 and conservative modifications thereof;

wherein the antibody specifically binds to human PD-L1.

11. The antibody or antigen-binding portion thereof of claim 10 , wherein the heavy chain variable region and light chain variable region CDR2 domains are selected from the group consisting of:

(a) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:31 and conservative modifications thereof; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:61 and conservative modifications thereof;

(b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:32 and conservative modifications thereof; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:62 and conservative modifications thereof;

(c) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:33 and conservative modifications thereof; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:63 and conservative modifications thereof;

(d) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:34 and conservative modifications thereof; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:64 and conservative modifications thereof;

(e) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:35 and conservative modifications thereof; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:65 and conservative modifications thereof;

(f) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:36 and conservative modifications thereof; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:66 and conservative modifications thereof;

(g) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:37 and conservative modifications thereof; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:67 and conservative modifications thereof;

(h) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:38 and conservative modifications thereof; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:68 and conservative modifications thereof;

(i) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:39 and conservative modifications thereof; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:69 and conservative modifications thereof; and

(j) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:40 and conservative modifications thereof; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:70 and conservative modifications thereof.

12. The antibody or antigen-binding portion thereof of claim 11 , wherein the heavy chain variable region and light chain variable region CDR1 domains are selected from the group consisting of:

(a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:21 and conservative modifications thereof; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:51 and conservative modifications thereof;

(b) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:22 and conservative modifications thereof; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:52 and conservative modifications thereof;

(c) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:23 and conservative modifications thereof; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:53 and conservative modifications thereof;

(d) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:24 and conservative modifications thereof; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:54 and conservative modifications thereof;

(e) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:25 and conservative modifications thereof; at and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:55 and conservative modifications thereof;

(f) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:26 and conservative modifications thereat and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:56 and conservative modifications thereof;

(g) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:27 and conservative modifications thereof; at and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:57 and conservative modifications thereof;

(h) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:28 and conservative modifications thereof; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:58 and conservative modifications thereof;

(i) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:29 and conservative modifications thereof; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:59 and conservative modifications thereof; and

(j) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:30 and conservative modifications thereof; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:60 and conservative modifications thereof.

13. An isolated monoclonal antibody, or antigen binding portion thereof, comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein the heavy chain variable region and light chain variable region CDR1, CDR2, and CDR3 domains are selected from the group consisting of:

(a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:21; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:31; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:41; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:51; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:61; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:71;

(b) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:22; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:32; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:42; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:52; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:62; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:72;

(c) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:23; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:33; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:43; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:53; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:63; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:73;

(d) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:24; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:34; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:44; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:54; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:64; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:74;

(e) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:25; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:35; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:45; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:55; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:65; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:75;

(f) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:26; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:36; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:46; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:56; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:66; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:76;

(g) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:27; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:37; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:47; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:57; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:67; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:77;

(h) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:28; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:38; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:48; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:58; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:68; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:78;

(i) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:29; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:39; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:49; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:59; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:69; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:79; and

(j) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:30; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:40; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:50; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:60; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:70; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:80;

wherein the antibody specifically binds to PD-L1.

14. The antibody or antigen-binding portion thereof of claim 13 , which comprises:

(a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:21;

(b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 31;

(d) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:51;

(e) a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:61; and

(f) a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:71.

15. The antibody or antigen-binding portion thereof of claim 13 , which comprises:

(a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:22;

(b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:32;

(d) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:52;

(e) a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:62; and

(f) a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:72.

16. The antibody or antigen-binding portion thereof of claim 13 , which comprises:

(a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:23;

(b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:33;

(d) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:53;

(e) a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:63; and

(f) a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:73.

17. An isolated monoclonal antibody, or antigen binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and light chain variable region are selected from the group consisting of:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:1; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:11;

(b) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:2; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:12;

(c) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:3; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:13;

(d) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:4; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:14;

(e) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:5; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:15;

(f) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:6; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:16;

(g) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:7; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:17;

(h) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:8; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:18;

(i) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:9; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:19; and

(j) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:10; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:20;

wherein the antibody specifically binds to PD-L1.

18. The antibody or antigen-binding portion thereof of claim 17 , which comprises:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:1; and

(b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:11.

19. The antibody or antigen-binding portion thereof of claim 17 , which comprises:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:2; and

(b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:12.

20. The antibody or antigen-binding portion thereof of claim 17 , which comprises:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:3; and

(b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:13.

21. A composition comprising the antibody, or antigen-binding portion thereof, of any one of claims 1 , 13 , and 17 , and a pharmaceutically acceptable carrier.

22. An immunoconjugate comprising the antibody, or antigen-binding portion thereof, of any one of claims 1 , 13 , and 17 , linked to a therapeutic agent.

23. The immunoconjugate of claim 22 , wherein the therapeutic agent is a cytotoxin or a radioactive isotope.

24. A bispecific molecule comprising the antibody, or antigen-binding portion thereof, of any one of claims 1 , 13 , and 17 , linked to a second functional moiety having a different binding specificity than said antibody, or antigen binding portion thereof.

25. The antibody or antigen-binding portion thereof of any one of claims 1 , 13 , and 17 wherein the antibody is IgG4 isotype.

26. An isolated human monoclonal antibody, or an antigen-binding portion thereof, comprising:

(a) a heavy chain variable region that comprises amino acids having a sequence derived from a human V H 1-69 germline sequence; and a light chain variable region that comprises amino acids having a sequence derived from a human V K A27 germline sequence;

(b) a heavy chain variable region that comprises amino acids having a sequence derived from a human V H 3-9 germline sequence; and a light chain variable region that comprises amino acids having a sequence derived from a human V K L15 germline sequence; or

(c) a heavy chain variable region that comprises amino acids having a sequence that is derived from a human V H 3-9 germline sequence; and a light chain variable region that comprises amino acids having a sequence derived from a human V K L18 germline sequence;

wherein the antibody specifically binds to PD-L1.

Assignments (4)

MERGER Recorded Mar 19, 2015

From: MEDAREX, L.L.C.

To: E. R. SQUIBB & SONS, L.L.C.

Reel/Frame 035226/0690 →

MERGER Recorded Jun 13, 2013

From: MEDAREX, INC.

To: MEDAREX, L.L.C.

Reel/Frame 030603/0924 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2009

From: KORMAN, ALAN J.; SELBY, MARK J.; WANG, CHANGYU; SRINIVASAN, MOHAN; PASSMORE, DAVID; HUANG, HAICHUN; CHEN, HAIBIN

To: MEDAREX, INC.

Reel/Frame 022788/0944 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2008

From: KORMAN, ALAN J.; SELBY, MARK J.; WANG, CHANGYU; SRINIVASAN, MOHAN; PASSMORE, DAVID B.; HUANG, HAICHUN; CHEN, HAIBIN

To: MEDAREX, INC.

Reel/Frame 021065/0278 →